Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
PARIS, Jan. 29, 2016 -- NEOVACS (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today its financial reporting calendar for 2016.
Financial publications will be released prior to the opening of the Paris stock exchange. This calendar is indicative and subject to change.
| -- 2015 Full-Year Results | March 7, 2016 | |||
| -- Shareholders’ AGM | April 12, 2016 | |||
| -- 2016 Half-Year results | October 14, 2016 |
About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.
